Drugs that contain Rufinamide

1. Drug name - BANZEL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6740669 EISAI INC Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic
Nov, 2022

(a month from now)

CN1217716A EISAI INC Improved Crystalline Body Of Medicine
Jun, 2018

(4 years ago)

CN1132820C EISAI INC Improved Crystalline Body Of Medicine
Jun, 2018

(4 years ago)

CN1572789A EISAI INC 1 - (2, 6-Difluorobenzyl) -1H-1, 2, 3-Triazole - -4 - Crystalline Modified Bodies Of Carboxamides And Their Use As Antiepileptic Drug
Jun, 2018

(4 years ago)

CN1298708C EISAI INC 1 - (2, 6-Difluorobenzyl) -1H-1, 2, 3-Triazole - -4 - Crystalline Modified Bodies Of Carboxamides And Use Thereof
Jun, 2018

(4 years ago)

CN1259127A EISAI INC 1 - (2, 6-Difluorobenzyl) -1H-1, 2, 3-Triazole - -4 - Crystalline Modified Bodies Of Carboxamides And Their Use As Antiepileptic Drug
Jun, 2018

(4 years ago)

CN1159300C EISAI INC 1 - (2, 6-Difluorobenzyl) -1H-1, 2, 3-Triazole - -4 - Crystalline Modified Bodies Of Carboxamides And Their Use As Antiepileptic Drug
Jun, 2018

(4 years ago)

EP994864B1 EISAI INC Crystal Modification Of 1-(2,6-Difluorobenzyl)-1H-1,2,3-Triazole-4-Carboxamide And Its Use As Antiepileptic
Jun, 2018

(4 years ago)

EP994864A1 EISAI INC Crystal Modification Of 1-(2,6-Difluorobenzyl)-1H-1,2,3-Triazole-4-Carboxamide And Its Use As Antiepileptic
Jun, 2018

(4 years ago)

EP994863B1 EISAI INC Crystal Modification Of 1-(2,6-Difluorobenzyl)-1H-1,2,3-Triazole-4-Carboxamide And Its Use As Antiepileptic
Jan, 2022

(8 months ago)

EP994863A1 EISAI INC Crystal Modification Of 1-(2,6-Difluorobenzyl)-1H-1,2,3-Triazole-4-Carboxamide And Its Use As Antiepileptic
Jan, 2022

(8 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6740669

(Pediatric)

EISAI INC Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic May, 2023

(7 months from now)

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage
Strength Dosage Availability
40MG/ML SUSPENSION;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.